U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H19N3O5S
Molecular Weight 461.49
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of PIROXICAM CINNAMATE

SMILES

CN1C(C(=O)NC2=NC=CC=C2)=C(OC(=O)\C=C\C3=CC=CC=C3)C4=C(C=CC=C4)S1(=O)=O

InChI

InChIKey=GPUVGQIASQNZET-CCEZHUSRSA-N
InChI=1S/C24H19N3O5S/c1-27-22(24(29)26-20-13-7-8-16-25-20)23(18-11-5-6-12-19(18)33(27,30)31)32-21(28)15-14-17-9-3-2-4-10-17/h2-16H,1H3,(H,25,26,29)/b15-14+

HIDE SMILES / InChI
Piroxicam cinnamate (Cinnoxicam) is the anti-inflammatory agent. It is a cyclooxygenase inhibitor. Cinnoxicam was used in patients with inflammatory-degenerative osteoarticular diseases. The treatment brought about a significant improvement in the clinical variables considered (spontaneous pain at rest and on movement and functional limitation), which was observed within a few days of starting therapy. Tolerance was good, only a few slight side-effects having been reported. Cinnoxicam is a safe and reliable therapeutic option for men with oligoasthenospermia associated with a grade III varicocele, but surgery is better for those with grade II, IV and V. Piroxicam cinnamate as a long-acting prodrug is marketed by SPA in Italy for the treatment of rheumatic disorders.

Approval Year

PubMed

PubMed

TitleDatePubMed
Reduction in sperm aneuploidy levels in severe oligoasthenoteratospermic patients after medical therapy: a preliminary report.
2012-07
Unusual coordinating behavior by three non-steroidal anti-inflammatory drugs from the oxicam family towards copper(II). Synthesis, X-ray structure for copper(II)-isoxicam, -meloxicam and -cinnoxicam-derivative complexes, and cytotoxic activity for a copper(II)-piroxicam complex.
2007-08
Male idiopathic oligoasthenoteratozoospermia.
2006-03
Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocele-associated oligoasthenospermia.
2004-08-05
Medical therapy of oligoasthenospermia associated with left varicocele.
2003-04
[In vitro effects of L-carnitine on the inhibition of sperm mobility induced by FANS].
2000-08-25
Stability study of piroxicam and cinnoxicam in solid pharmaceuticals.
1999-06
[Clinical evaluation of 30 mg cinnoxicam in patients with osteoarthrosis. Double blind controlled trial].
1996-04
[Clinical evaluation of cinnoxicam 30 mg in patients with osteoarthrosis. A double-blind controlled study].
1996-03
Contact allergy to cinnoxicam.
1995-01
Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
1994-02
[Correlation of the lipophilicity of the active agents with their topical anti-inflammatory activity].
1992-07-01
[Combined clinico-thermographic findings for the evaluation of a topical anti-inflammatory agent. Study of cinnoxicam cream].
1991-07-01
[Evaluation of a new non-steroidal anti-inflammatory agent in degenerative osteo-articular pathology].
1991-06
[Analgesic activity of cinnoxicam. Findings of clinical sensimetry].
1989-12-15
[Clinical pharmacology of non-steroidal anti-inflammatory drugs. A new benzothiazine derivative: cinnoxicam].
1988-09
Patents
Name Type Language
PIROXICAM CINNAMIC ACID ESTER
MI  
Preferred Name English
PIROXICAM CINNAMATE
USAN   WHO-DD  
USAN  
Official Name English
SPA-S-510
Code English
PIROXICAM CINNAMATE [USAN]
Common Name English
SPA-S-51O
Code English
4-Hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide, cinnamate (ester)
Systematic Name English
Piroxicam cinnamate [WHO-DD]
Common Name English
PIROXICAM CINNAMIC ACID ESTER [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1323
Created by admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
Code System Code Type Description
CAS
87234-24-0
Created by admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
PRIMARY
EVMPD
SUB14900MIG
Created by admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
PRIMARY
RXCUI
33787
Created by admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
PRIMARY RxNorm
EPA CompTox
DTXSID10236212
Created by admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
PRIMARY
MERCK INDEX
m8889
Created by admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
PRIMARY Merck Index
USAN
W-149
Created by admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
PRIMARY
ChEMBL
CHEMBL2106889
Created by admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
PRIMARY
MESH
C057291
Created by admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
PRIMARY
NCI_THESAURUS
C73032
Created by admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
PRIMARY
DRUG CENTRAL
655
Created by admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
PRIMARY
FDA UNII
7E8Q32N75N
Created by admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
PRIMARY
SMS_ID
100000079144
Created by admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
PRIMARY
PUBCHEM
6436090
Created by admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
PRIMARY